Guanfacine Clinical Trial for Smoking Cessation

Diseases and Conditions Researched

Smoking Cessation

What is the purpose of this trial?

Adult daily smokers motivated to quit smoking will be randomized to extended-release guanfacine (6mg/day) or placebo and will enroll in an 8-week treatment period combining medication with brief behavioral support. The investigators hypothesize that the active dose of guanfacine compared to placebo will increase rates of prolonged smoking abstinence at the end of the 8-week treatment phase.


Participation Guidelines

Age: 18 Years - 65 Years
Gender: Both

This trial accepts healthy volunteers.

Click here for detailed participation information for this trial.

Sponsor: National Institute on Drug Abuse
Last Updated:
Study HIC#: 1110009133